Generic Name and Formulations:
Sodium hyaluronate 10mg/mL; soln for intra-articular inj.
Ferring Pharmaceuticals, Inc.
Indications for EUFLEXXA:
Osteoarthritis of the knee in patients who have failed nonpharmacologic therapy and analgesics (eg, acetaminophen).
Prior to treatment: remove joint effusion (use separate syringe), if present. Inject 2mL (full syringe contents) intra-articularly in each affected knee weekly for 3 weeks. Use separate syringes for each knee.
Knee joint infection or skin disease at inj site.
Repeated treatment cycles: not established. Avoid intravascular injection. Avoid strenuous activity within 48hrs after injection. Pregnancy. Nursing mothers.
Avoid disinfectants with quaternary ammonium salts. Concomitant other intra-articular injectables: not recommended.
Arthralgia, increase blood pressure, inj site pain, local reactions, transient knee inflammation.
Single-use prefilled syringes (2mL)—1
Renal and Urology News Articles
- Gadolinium-Based Contrast May Up Acute Kidney Injury Risk in CKD
- Delayed Prostate Cancer Treatment May Up Relapse Risk
- Review: Desmopressin Decreases Nocturia Episodes
- Surgery, Radiation Regimens for High-Grade PCa Offer Similar Outcomes
- Salvage Prostatectomy May Benefit Some Prostate Cancer Patients
- Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading
- Nocturia, Overactive Bladder Improved With PTNS
- Many Americans Unaware of Promise of Personalized Medicine
- Noninferior CV Outcomes for Linagliptin in T2D With High CV, Renal Risk
- VDRAs Do Not Lower Cardiovascular Event Risk in HD
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)